Business Context and Reporting Period
Company: Bioaffinity Technologies, Inc. (BIAF)
Filing Type: Form 8-K (Current Report)
Date of Report: February 19, 2026
Reporting Period: Single event date (February 19, 2026)
Business Overview: The registrant is a Delaware corporation listed on the Nasdaq Capital Market. It is designated as an emerging growth company. The filing reports a specific corporate event regarding a clinical case study rather than periodic financial results.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This Form 8-K is a current report focused on a specific event and does not contain financial statements or quantitative financial data.
Material Changes
No material financial changes versus a prior comparable period are reported in this document. The filing details a non-financial operational update: the release of a new clinical case study demonstrating the utility of the company's CyPath® Lung product in determining treatment for a patient with a suspicious lung finding.
Guidance, Outlook, and Management Commentary
- Event Description: On February 19, 2026, the company issued a press release (Exhibit 99.1) announcing a clinical case study involving a 79-year-old female patient.
- Product Focus: The study highlights the application of CyPath® Lung in analyzing low-dose computed tomography (LDCT) scans.
- Management Commentary: No forward-looking guidance, financial outlook, or specific risk factors are detailed within the body of this 8-K filing beyond the reference to the attached press release.
Investor Verification Checklist
- Review the attached press release (Exhibit 99.1) for full details on the clinical case study methodology and outcomes.
- Verify the regulatory status and market adoption of the CyPath® Lung product.
- Check subsequent filings (e.g., 10-Q or 10-K) for financial performance data, as this 8-K contains no financial metrics.
- Confirm the company's continued status as an emerging growth company and any implications for financial reporting standards.